Dr. Eric Kumar Singhi, MD

Dr. Singhi practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Singhi's NPI, 1811341720, was assigned on April 17, 2016. Dr. Singhi graduated from Medical University of South Carolina College of Medicine in 2016. Dr. Singhi holds Texas license T7045.

Dr. Singhi's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Singhi's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Singhi practices. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Singhi's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Singhi is board certified in hematology by the American Board of Internal Medicine. Dmand AI has Dr. Singhi's licenses on file in 10 states: Texas, Florida, Arizona, Georgia, Mississippi, Oklahoma, Tennessee, Alabama, Louisiana and Washington.

Dmand AI lists fluid and electrolyte imbalances and lung cancer among the conditions Dr. Singhi treats.

CMS data shows 507 Medicare services from Dr. Singhi across 4 procedure codes in 2024, for 150 Medicare patients. Medicare paid $55,394 for them.

CMS counts 150 Medicare patients who saw Dr. Singhi in 2024. The largest group is 65 to 74, with 100 patients. 75% of them have cancer, and 75% have high blood pressure. Their average risk score is 2.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Singhi's median patient age at 73, with 58% women.

In 2024, Dr. Singhi wrote 284 Medicare Part D claims for 65 patients. 46% of them were for generic drugs. CMS names the drug for 169 of them, across 6 drugs with 11 or more claims each, at $1,987,852 in total drug cost. In 2023, CMS named 59 claims across 4 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Singhi for performance year 2024, reported as part of a group. Dr. Singhi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Singhi as offering telehealth.

Dmand AI links 20 papers to Dr. Singhi, published from 2013 to 2025. 2018 was the busiest year, with 3. The most frequent topics are Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung and Lung Neoplasms. Dr. Singhi has published most often in JAMA Oncol. Dr. Singhi's most frequent co-authors are Carl Michael Gay, MD, PhD, John V. Heymach, MD and Arthi Sridhar, MD.

CMS Open Payments shows 91 general payments to Dr. Singhi from 18 drug and device companies from 2022 to 2025. Consulting fees make up the largest share, 84% of the total. AstraZeneca Pharmaceuticals LP paid the most, $20,062.

Dmand AI lists 2 awards for Dr. Singhi.

Dr. Singhi graduated from Medical University of South Carolina College of Medicine in 2016. Dr. Singhi is a member of AOA, ACP, AMA, ASCO, ASH and Gold Humanism Honor Society.

Dr. Singhi is in network with 4 carriers, including Aetna, Elevance and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 3. Check the plan with the practice before a visit.